Consolidation Chemotherapy Rather than Induction Chemotherapy Can Prolong the Survival Rate of Inoperable Esophageal Cancer Patients Who Received Concurrent Chemoradiotherapy.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 9502503 Publication Model: Electronic Cited Medium: Internet ISSN: 1718-7729 (Electronic) Linking ISSN: 11980052 NLM ISO Abbreviation: Curr Oncol Subsets: MEDLINE

Publication: 2021- : Basel, Switzerland : MDPI
Original Publication: Toronto : Multimed, c1994-

Consolidation Chemotherapy* ; Esophageal Neoplasms*/drug therapy; Chemoradiotherapy ; Humans ; Induction Chemotherapy ; Retrospective Studies ; Survival Rate

Concurrent chemoradiotherapy (CRT) is regarded as the standard treatment for inoperable esophageal cancers (EC). It is still controversial whether consolidation chemotherapy (CCT) or induction chemotherapy (IC) is beneficial for the patients who received CRT. Therefore, we carried out a retrospective analysis at our institution. A total of 186 inoperable EC patients from 20 October 2017 to 7 June 2021 who have previously received CRT were included in our study. The patients were divided into IC + CRT (n = 52), CCRT (n = 64), and CRT + CCT (n = 70) groups according to whether they received induction chemotherapy, consolidation chemotherapy, or not. We used Kaplan−Meier statistics to analyze their 1-, 2-, and 3-year OS. The median follow-up time for the whole group was 14.15 months. The 1-, 2-, 3- year overall survival (OS) for the CCRT group were 72.2%, 52.5%, and 29.5%, and 50.9%, 37.5%, and 25% for the IC + CRT group (p > 0.05). For the CRT + CCT group,1-, 2-, and 3-year OS were 89.8%, 59.0%, and 42.5% (p < 0.05). Adverse reactions in the three groups were mainly graded 0−3. The difference between the three groups was not statistically significant (p > 0.05). For non-surgical EC patients who received CRT, CCT after CRT but not IC before CRT can improve 1-, 2-, and 3-year OS with a low incidence of associated severe adverse effects. As a result, the addition of consolidation chemotherapy to chemoradiotherapy has significant prognostic advantages for inoperable EC patients.

Radiat Oncol. 2018 Aug 15;13(1):150. (PMID: 30111361)
Int J Clin Oncol. 2017 Apr;22(2):229-236. (PMID: 28005209)
Clin Oncol (R Coll Radiol). 2011 Apr;23(3):182-8. (PMID: 21232928)
Radiat Oncol. 2017 Mar 7;12(1):47. (PMID: 28270162)
J Chin Med Assoc. 2017 Oct;80(10):636-643. (PMID: 28716602)
Arch Med Res. 2020 Jul;51(5):419-428. (PMID: 32418649)
Nat Commun. 2021 Jun 29;12(1):4014. (PMID: 34188053)
Lancet. 2013 Feb 2;381(9864):400-12. (PMID: 23374478)
Eur J Cancer. 2021 Jun;150:214-223. (PMID: 33934058)
Ann Surg. 2019 Jan;269(1):83-87. (PMID: 28742685)
Lancet Oncol. 2015 Sep;16(9):1090-1098. (PMID: 26254683)
Sci Rep. 2017 Dec 4;7(1):16870. (PMID: 29203855)
J Cancer. 2017 Sep 20;8(17):3441-3447. (PMID: 29151927)
Radiat Oncol. 2015 May 21;10:116. (PMID: 25994051)
Anticancer Res. 2020 Mar;40(3):1771-1778. (PMID: 32132086)
Med Sci Monit. 2018 Jun 19;24:4183-4191. (PMID: 29915168)
Front Oncol. 2022 May 23;12:813021. (PMID: 35677167)
BMC Cancer. 2015 Oct 16;15:715. (PMID: 26474893)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Jpn J Clin Oncol. 2019 Dec 18;49(11):1055-1060. (PMID: 31411696)
Cancer Chemother Pharmacol. 2016 Jul;78(1):91-9. (PMID: 27193097)
J Clin Oncol. 1996 Jan;14(1):149-55. (PMID: 8558190)
J Pain Symptom Manage. 2013 Mar;45(3):534-41. (PMID: 22917716)
Jpn J Clin Oncol. 2016 Sep;46(9):805-10. (PMID: 27380810)
Int J Radiat Oncol Biol Phys. 2015 Mar 1;91(3):489-96. (PMID: 25680595)
Front Oncol. 2021 Jan 07;10:604657. (PMID: 33489910)
J Gynecol Oncol. 2017 Jan;28(1):e15. (PMID: 27958682)
J Clin Oncol. 2021 Jun 20;39(18):1995-2004. (PMID: 33891478)
Oncologist. 2007 Apr;12(4):451-64. (PMID: 17470688)
J Gastrointest Cancer. 2020 Jun;51(2):498-505. (PMID: 31240598)
Am Fam Physician. 2017 Jan 1;95(1):22-28. (PMID: 28075104)
J Clin Oncol. 2009 Jan 10;27(2):242-9. (PMID: 19064973)
N Engl J Med. 2012 May 31;366(22):2074-84. (PMID: 22646630)
Front Oncol. 2021 Sep 13;11:665231. (PMID: 34589418)

Keywords: concurrent chemoradiotherapy; consolidation chemotherapy; esophageal cancer; induction chemotherapy

Date Created: 20220922 Date Completed: 20220923 Latest Revision: 20230308

20240104

PMC9498234

10.3390/curroncol29090499

36135068